Cortex Begins Human Trials of Alzheimer’s Drug

Cortex Pharmaceuticals Inc. has started human clinical trials with a drug it is developing for treatment of memory loss resulting from Alzheimer’s disease.

The firm said the study of its Ampakine product is aimed at gaining knowledge of the safety of the compound on humans. The study, being conducted in Berlin, involves 48 people and will last about six weeks. Earlier this year, the company reported that tests of Ampakine on rats showed that animals treated with the drug performed significantly better than untreated animals.